Clinical Trial Update: Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis [Phase 4]

View source ↗

Summary

Phase 4 trial update on anti-inflammatory effects of a tazarotene/halobetasol lotion in psoriasis vulgaris.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• 0.045% tazarotene/0.01% halobetasol lotion

Snippet

Sponsor: Dermatology Consulting Services, PLLC | Conditions: Psoriasis Vulgaris | Phase 4 | Status: COMPLETED